BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20052743)

  • 1. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Am J Hematol; 2010 Feb; 85(2):97-100. PubMed ID: 20052743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
    Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
    Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocytosis and risk stratification assessment in essential thrombocythemia.
    Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
    J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
    Chou YS; Gau JP; Yu YB; Pai JT; Hsiao LT; Liu JH; Hong YC; Liu CY; Yang CF; Chen PM; Chiou TJ; Tzeng CH
    Eur J Haematol; 2013 Mar; 90(3):228-36. PubMed ID: 23281576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
    Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
    Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.
    Palandri F; Polverelli N; Catani L; Ottaviani E; Baccarani M; Vianelli N
    Ann Hematol; 2011 Aug; 90(8):933-8. PubMed ID: 21287350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
    Caramazza D; Caracciolo C; Barone R; Malato A; Saccullo G; Cigna V; Berretta S; Schinocca L; Quintini G; Abbadessa V; Di Raimondo F; Siragusa S
    Ann Hematol; 2009 Oct; 88(10):967-71. PubMed ID: 19214510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.
    Carobbio A; Ferrari A; Masciulli A; Ghirardi A; Barosi G; Barbui T
    Blood Adv; 2019 Jun; 3(11):1729-1737. PubMed ID: 31175128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study.
    Gisslinger H; Müllner M; Pabinger I; Heis-Vahidi-Fard N; Gisslinger B; Brichta A; Bachleitner-Hofmann T; Mannhalter C
    Haematologica; 2005 Mar; 90(3):408-10. PubMed ID: 15749677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
    Passamonti F; Rumi E; Pungolino E; Malabarba L; Bertazzoni P; Valentini M; Orlandi E; Arcaini L; Brusamolino E; Pascutto C; Cazzola M; Morra E; Lazzarino M
    Am J Med; 2004 Nov; 117(10):755-61. PubMed ID: 15541325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.
    Tefferi A; Gangat N; Wolanskyj AP; Schwager S; Pardanani A; Lasho TL; Mesa R; McClure RF; Li CY; Hanson CA
    Eur J Haematol; 2008 May; 80(5):386-90. PubMed ID: 18221390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
    Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
    Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.